MetaADEDB 2.0 @ LMMD
Midodrine
(MGCQZNBCJBRZDT-UHFFFAOYSA-N)
Structure
SMILES
COc1ccc(cc1C(CNC(=O)CN)O)OC.Cl
Molecular Formula:
C12H19ClN2O4
Molecular Weight:
290.743
Log P:
1.7053
Hydrogen Bond Acceptor:
6
Hydrogen Bond Donor:
4
TPSA:
93.81
CAS Number(s):
3092-17-9; 43218-56-0
Synonym(s)
1.
Midodrine
2.
Amatine
3.
Gutron
4.
Midodrin
5.
Midodrine Hydrochloride
6.
Midodrine Monohydrochloride
7.
Midon
8.
ProAmatine
9.
ST-1085
10.
Monohydrochloride, Midodrine
11.
ST 1085
12.
ST1085
External Link(s)
MeSHD008879
PubChem Compound11426313
25137866
18340
ChEBI31847
CHEMBLCHEMBL1200461
KEGGdr:D01307
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Drug ineffectiveFAERS: 18US FAERS
2HeadacheFAERS: 13US FAERS
3NauseaFAERS: 9US FAERS
4DizzinessFAERS: 7US FAERS
5Dry gangreneFAERS: 5US FAERS
6HypotensionFAERS: 5US FAERS
7Skin UlcerFAERS: 5US FAERS
8VomitingFAERS: 5US FAERS
9Chest PainFAERS: 4US FAERS
10ErythemaFAERS: 4US FAERS
11Feeling abnormalFAERS: 4US FAERS
12BradycardiaFAERS: 3US FAERS
13DysuriaFAERS: 3US FAERS
14HypersensitivityFAERS: 3US FAERS
15InfectionFAERS: 3US FAERS
16PainFAERS: 3US FAERS
17Pharmaceutical product complaintFAERS: 3US FAERS
18PruritusFAERS: 3US FAERS
19SomnolenceFAERS: 3US FAERS
20SyncopeFAERS: 3US FAERS
21Therapeutic response unexpected with drug substitutionFAERS: 3US FAERS
22UrticariaFAERS: 3US FAERS
23Abdominal PainFAERS: 2US FAERS
24Abdominal discomfortFAERS: 2US FAERS
25AstheniaFAERS: 2US FAERS
26DisorientationFAERS: 2US FAERS
27Drug dispensing errorFAERS: 2US FAERS
28DysarthriaFAERS: 2US FAERS
29LeukoencephalopathyFAERS: 2US FAERS
30MalaiseFAERS: 2US FAERS
31PalpitationsFAERS: 2US FAERS
32PiloerectionFAERS: 2
Canada Vigilance: 1
Canada Vigilance
US FAERS
33SnoringFAERS: 2US FAERS
34Sperm count decreasedFAERS: 2US FAERS
35SwellingFAERS: 2US FAERS
36Activities of daily living impairedFAERS: 1US FAERS
37AgitationFAERS: 1US FAERS
38AlopeciaFAERS: 1US FAERS
39AngerFAERS: 1US FAERS
40AngioedemaFAERS: 1US FAERS
41AnxietyFAERS: 1US FAERS
42Arterial insufficiencyFAERS: 1US FAERS
43Atrial FibrillationFAERS: 1US FAERS
44Blood pressure fluctuationFAERS: 1US FAERS
45Chest discomfortFAERS: 1US FAERS
46ChillsFAERS: 1
Canada Vigilance: 1
Canada Vigilance
US FAERS
47Drug exposure during pregnancyFAERS: 1US FAERS
48Drug withdrawal syndromeFAERS: 1US FAERS
49DysgeusiaFAERS: 1US FAERS
50Electrocardiogram abnormalFAERS: 1US FAERS
51EpistaxisFAERS: 1US FAERS
52Eye InfectionFAERS: 1US FAERS
53Eye painFAERS: 1US FAERS
54FatigueFAERS: 1US FAERS
55Fluid overloadFAERS: 1US FAERS
56FlushingFAERS: 1US FAERS
57FormicationFAERS: 1US FAERS
58Head discomfortFAERS: 1US FAERS
59HydronephrosisFAERS: 1US FAERS
60Hypertensive cardiomyopathyFAERS: 1US FAERS
61Inappropriate schedule of drug administrationFAERS: 1US FAERS
62Incorrect dose administeredFAERS: 1US FAERS
63IndurationFAERS: 1US FAERS
64Intentional product misuseFAERS: 1US FAERS
65Intestinal ObstructionFAERS: 1US FAERS
66Joint swellingFAERS: 1US FAERS
67LeukopeniaFAERS: 1US FAERS
68Maternal exposure during pregnancyFAERS: 1US FAERS
69Medication ErrorFAERS: 1US FAERS
70Middle insomniaFAERS: 1US FAERS
71Mouth swellingFAERS: 1US FAERS
72Myocardial InfarctionFAERS: 1US FAERS
73NecrosisFAERS: 1US FAERS
74Night sweatsFAERS: 1US FAERS
75Nipple painFAERS: 1US FAERS
76OverdoseFAERS: 1US FAERS
77Peripheral swellingFAERS: 1US FAERS
78PneumoniaFAERS: 1US FAERS
79PneumothoraxFAERS: 1US FAERS
80PregnancyFAERS: 1US FAERS
81Prescribed overdoseFAERS: 1US FAERS
82Pressure of speechFAERS: 1US FAERS
83Product label issueFAERS: 1US FAERS
84Product quality issueFAERS: 1US FAERS
85Product solubility abnormalFAERS: 1US FAERS
86Product substitution issueFAERS: 1US FAERS
87Product use in unapproved indicationFAERS: 1US FAERS
88Prostatic painFAERS: 1US FAERS
89Respiratory FailureFAERS: 1US FAERS
90Respiratory arrestFAERS: 1US FAERS
91RestlessnessFAERS: 1US FAERS
92RosaceaFAERS: 1US FAERS
93ShockFAERS: 1US FAERS
94Skin necrosisFAERS: 1US FAERS
95Suicide attemptFAERS: 1US FAERS
96TachycardiaFAERS: 1US FAERS
97TremorFAERS: 1US FAERS
98Unevaluable eventFAERS: 1US FAERS
99Urinary tract infectionFAERS: 1US FAERS
100Vascular calcificationFAERS: 1US FAERS
101Vascular occlusionFAERS: 1US FAERS
102Visual ImpairmentFAERS: 1US FAERS
103Wrong technique in product usage processFAERS: 1US FAERS
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120239

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.